WO1996001830A1 - Silylmethyl-aniline derivatives, methods of preparation and use thereof as drugs - Google Patents
Silylmethyl-aniline derivatives, methods of preparation and use thereof as drugs Download PDFInfo
- Publication number
- WO1996001830A1 WO1996001830A1 PCT/FR1995/000916 FR9500916W WO9601830A1 WO 1996001830 A1 WO1996001830 A1 WO 1996001830A1 FR 9500916 W FR9500916 W FR 9500916W WO 9601830 A1 WO9601830 A1 WO 9601830A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phenyl
- methyl
- aromatic
- dimethyl
- derivative
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 9
- 238000000034 method Methods 0.000 title abstract description 51
- 238000002360 preparation method Methods 0.000 title abstract description 10
- 229940079593 drug Drugs 0.000 title description 4
- DIPKHWZGTFSZMZ-UHFFFAOYSA-N N-(silylmethyl)aniline Chemical class [SiH3]CNC1=CC=CC=C1 DIPKHWZGTFSZMZ-UHFFFAOYSA-N 0.000 title description 2
- -1 Aromatic silyl-methylamine derivatives Chemical class 0.000 claims abstract description 47
- 125000003118 aryl group Chemical group 0.000 claims abstract description 28
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 10
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 7
- 125000000524 functional group Chemical group 0.000 claims abstract description 7
- 150000004982 aromatic amines Chemical class 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 39
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 32
- 150000001412 amines Chemical class 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 11
- 150000003254 radicals Chemical class 0.000 claims description 11
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 9
- 239000000460 chlorine Substances 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical group 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 150000001408 amides Chemical class 0.000 claims description 8
- 230000007170 pathology Effects 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 229910052794 bromium Inorganic materials 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 150000002825 nitriles Chemical class 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 6
- 239000004202 carbamide Substances 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 229940124530 sulfonamide Drugs 0.000 claims description 6
- 150000003456 sulfonamides Chemical class 0.000 claims description 6
- 150000003568 thioethers Chemical group 0.000 claims description 6
- 150000003573 thiols Chemical group 0.000 claims description 6
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 229910052740 iodine Inorganic materials 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 229910052710 silicon Inorganic materials 0.000 claims description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- 125000003158 alcohol group Chemical group 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 239000011630 iodine Substances 0.000 claims description 4
- 150000002576 ketones Chemical class 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 3
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 claims description 3
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 claims description 3
- 230000000302 ischemic effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 230000002093 peripheral effect Effects 0.000 claims description 3
- 239000002243 precursor Substances 0.000 claims description 3
- 208000030090 Acute Disease Diseases 0.000 claims description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- FIQIEWYXLLEXNR-UHFFFAOYSA-N [O-][N+](=O)S(=O)(=O)[N+]([O-])=O Chemical compound [O-][N+](=O)S(=O)(=O)[N+]([O-])=O FIQIEWYXLLEXNR-UHFFFAOYSA-N 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 125000004423 acyloxy group Chemical group 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 208000037976 chronic inflammation Diseases 0.000 claims description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 2
- 230000003412 degenerative effect Effects 0.000 claims description 2
- 125000004188 dichlorophenyl group Chemical group 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 208000031225 myocardial ischemia Diseases 0.000 claims description 2
- ZHCAAFJSYLFLPX-UHFFFAOYSA-N nitrocyclohexatriene Chemical group [O-][N+](=O)C1=CC=C=C[CH]1 ZHCAAFJSYLFLPX-UHFFFAOYSA-N 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 150000003457 sulfones Chemical class 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 230000000472 traumatic effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 4
- LIWAQLJGPBVORC-UHFFFAOYSA-N ethylmethylamine Chemical compound CCNC LIWAQLJGPBVORC-UHFFFAOYSA-N 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 238000009833 condensation Methods 0.000 abstract description 19
- 230000005494 condensation Effects 0.000 abstract description 19
- 230000008569 process Effects 0.000 abstract description 4
- 238000003786 synthesis reaction Methods 0.000 description 45
- 230000015572 biosynthetic process Effects 0.000 description 42
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 32
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 239000000243 solution Substances 0.000 description 23
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 17
- 102000007330 LDL Lipoproteins Human genes 0.000 description 16
- 108010007622 LDL Lipoproteins Proteins 0.000 description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
- 229930003427 Vitamin E Natural products 0.000 description 16
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- 235000019165 vitamin E Nutrition 0.000 description 16
- 239000011709 vitamin E Substances 0.000 description 16
- 229940046009 vitamin E Drugs 0.000 description 16
- 239000000047 product Substances 0.000 description 15
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 238000010511 deprotection reaction Methods 0.000 description 11
- 230000003647 oxidation Effects 0.000 description 11
- 238000007254 oxidation reaction Methods 0.000 description 11
- JJYPMNFTHPTTDI-UHFFFAOYSA-N 3-methylaniline Chemical compound CC1=CC=CC(N)=C1 JJYPMNFTHPTTDI-UHFFFAOYSA-N 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000003963 antioxidant agent Substances 0.000 description 9
- 230000003078 antioxidant effect Effects 0.000 description 9
- 235000006708 antioxidants Nutrition 0.000 description 9
- 239000000543 intermediate Substances 0.000 description 9
- 239000012429 reaction media Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 239000012279 sodium borohydride Substances 0.000 description 8
- 229910000033 sodium borohydride Inorganic materials 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- FZERHIULMFGESH-UHFFFAOYSA-N N-phenylacetamide Chemical compound CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 description 7
- RJCTVFQQNCNBHG-UHFFFAOYSA-N chloromethyl-dimethyl-phenylsilane Chemical compound ClC[Si](C)(C)C1=CC=CC=C1 RJCTVFQQNCNBHG-UHFFFAOYSA-N 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 239000000377 silicon dioxide Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 230000001590 oxidative effect Effects 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 229910000077 silane Inorganic materials 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- OJGMBLNIHDZDGS-UHFFFAOYSA-N N-Ethylaniline Chemical compound CCNC1=CC=CC=C1 OJGMBLNIHDZDGS-UHFFFAOYSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- NEELRQATXZDUIR-UHFFFAOYSA-N n-[[dimethyl(phenyl)silyl]methyl]-3-methylaniline Chemical compound CC1=CC=CC(NC[Si](C)(C)C=2C=CC=CC=2)=C1 NEELRQATXZDUIR-UHFFFAOYSA-N 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- DZVYFCKCKXJQJE-UHFFFAOYSA-N 3-[[dimethyl(phenyl)silyl]methylamino]benzonitrile Chemical compound C1(=CC=CC=C1)[Si](C)(C)CNC1=CC(=CC=C1)C#N DZVYFCKCKXJQJE-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- AFDVQKVHKBTVDM-UHFFFAOYSA-N N-[[dimethyl(phenyl)silyl]methyl]-N-ethyl-5,6,7,8-tetrahydronaphthalen-1-amine Chemical compound C=1C=CC=2CCCCC=2C=1N(CC)C[Si](C)(C)C1=CC=CC=C1 AFDVQKVHKBTVDM-UHFFFAOYSA-N 0.000 description 4
- PXYCAGGZPXRJRW-UHFFFAOYSA-N N-[[dimethyl(phenyl)silyl]methyl]naphthalen-2-amine Chemical compound C[Si](C1=CC=CC=C1)(C)CNC1=CC2=CC=CC=C2C=C1 PXYCAGGZPXRJRW-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- RQAXKSVAARYPCX-UHFFFAOYSA-N chloromethyl-(2,3-dimethylphenyl)silane Chemical compound ClC[SiH2]C1=C(C(=CC=C1)C)C RQAXKSVAARYPCX-UHFFFAOYSA-N 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000007907 direct compression Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 238000005502 peroxidation Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 3
- TVCNEUXNMUNPOA-UHFFFAOYSA-N C1(=CC=CC=C1)[Si](C)(C)CNC1=CC(=CC=C1)C=C Chemical compound C1(=CC=CC=C1)[Si](C)(C)CNC1=CC(=CC=C1)C=C TVCNEUXNMUNPOA-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- AWDNNTJQNXBYTF-UHFFFAOYSA-N N-[[dimethyl(phenyl)silyl]methyl]-4-methylaniline Chemical compound C1(=CC=CC=C1)[Si](C)(C)CNC1=CC=C(C=C1)C AWDNNTJQNXBYTF-UHFFFAOYSA-N 0.000 description 3
- PPDWVXDRIQMQAM-UHFFFAOYSA-N N-[[dimethyl(phenyl)silyl]methyl]quinolin-6-amine Chemical compound C1(=CC=CC=C1)[Si](C)(C)CNC=1C=C2C=CC=NC2=CC=1 PPDWVXDRIQMQAM-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 3
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- VGGRCVDNFAQIKO-UHFFFAOYSA-N formic anhydride Chemical compound O=COC=O VGGRCVDNFAQIKO-UHFFFAOYSA-N 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- RMZZKVZBFPMGGU-UHFFFAOYSA-N n-[[dimethyl(phenyl)silyl]methyl]-4-methoxyaniline Chemical compound C1=CC(OC)=CC=C1NC[Si](C)(C)C1=CC=CC=C1 RMZZKVZBFPMGGU-UHFFFAOYSA-N 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000010410 reperfusion Effects 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- CXAOUOQAQWLVEE-UHFFFAOYSA-N N-[[dimethyl(phenyl)silyl]methyl]-N-methylnaphthalen-1-amine Chemical compound C[Si](C1=CC=CC=C1)(C)CN(C1=CC=CC2=CC=CC=C12)C CXAOUOQAQWLVEE-UHFFFAOYSA-N 0.000 description 2
- GWLSJNZAGIMOLN-UHFFFAOYSA-N N-[[dimethyl(phenyl)silyl]methyl]-N-propylaniline Chemical compound C=1C=CC=CC=1N(CCC)C[Si](C)(C)C1=CC=CC=C1 GWLSJNZAGIMOLN-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 2
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000012039 electrophile Substances 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- PSFDQSOCUJVVGF-UHFFFAOYSA-N harman Chemical compound C12=CC=CC=C2NC2=C1C=CN=C2C PSFDQSOCUJVVGF-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- YPGCWEMNNLXISK-UHFFFAOYSA-N hydratropic acid Chemical compound OC(=O)C(C)C1=CC=CC=C1 YPGCWEMNNLXISK-UHFFFAOYSA-N 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- SIAPCJWMELPYOE-UHFFFAOYSA-N lithium hydride Chemical compound [LiH] SIAPCJWMELPYOE-UHFFFAOYSA-N 0.000 description 2
- 229910000103 lithium hydride Inorganic materials 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- NCBZRJODKRCREW-UHFFFAOYSA-N m-anisidine Chemical compound COC1=CC=CC(N)=C1 NCBZRJODKRCREW-UHFFFAOYSA-N 0.000 description 2
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- RNVCVTLRINQCPJ-UHFFFAOYSA-N o-toluidine Chemical compound CC1=CC=CC=C1N RNVCVTLRINQCPJ-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 150000002926 oxygen Chemical class 0.000 description 2
- RZXMPPFPUUCRFN-UHFFFAOYSA-N p-toluidine Chemical compound CC1=CC=C(N)C=C1 RZXMPPFPUUCRFN-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 229960003912 probucol Drugs 0.000 description 2
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 2
- 229940029284 trichlorofluoromethane Drugs 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
- CALRUSILVULFGV-UHFFFAOYSA-N 1-(6-amino-2h-quinolin-1-yl)-2,2,2-trifluoroethanone Chemical compound FC(F)(F)C(=O)N1CC=CC2=CC(N)=CC=C21 CALRUSILVULFGV-UHFFFAOYSA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 1
- RUFPHBVGCFYCNW-UHFFFAOYSA-N 1-naphthylamine Chemical compound C1=CC=C2C(N)=CC=CC2=C1 RUFPHBVGCFYCNW-UHFFFAOYSA-N 0.000 description 1
- VIYRJCIIFVJQJE-UHFFFAOYSA-N 2,2,2-trifluoro-n-(3-formylphenyl)acetamide Chemical compound FC(F)(F)C(=O)NC1=CC=CC(C=O)=C1 VIYRJCIIFVJQJE-UHFFFAOYSA-N 0.000 description 1
- UEZRDXDUQAKINL-UHFFFAOYSA-N 2,2,2-trifluoro-n-(4-phenylphenyl)acetamide Chemical compound C1=CC(NC(=O)C(F)(F)F)=CC=C1C1=CC=CC=C1 UEZRDXDUQAKINL-UHFFFAOYSA-N 0.000 description 1
- ZAFQUEIKNVCYBV-UHFFFAOYSA-N 2,2,2-trifluoro-n-[3-(1,3-oxazol-4-yl)phenyl]acetamide Chemical compound FC(F)(F)C(=O)NC1=CC=CC(C=2N=COC=2)=C1 ZAFQUEIKNVCYBV-UHFFFAOYSA-N 0.000 description 1
- LBQZDNKXORGQAD-UHFFFAOYSA-N 2,2,2-trifluoro-n-naphthalen-2-ylacetamide Chemical compound C1=CC=CC2=CC(NC(=O)C(F)(F)F)=CC=C21 LBQZDNKXORGQAD-UHFFFAOYSA-N 0.000 description 1
- NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical compound NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 1
- NTOIKDYVJIWVSU-UHFFFAOYSA-N 2,3-dihydroxy-2,3-bis(4-methylbenzoyl)butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)C(O)(C(O)=O)C(O)(C(O)=O)C(=O)C1=CC=C(C)C=C1 NTOIKDYVJIWVSU-UHFFFAOYSA-N 0.000 description 1
- MEVXSUZBFYZPHZ-UHFFFAOYSA-N 2-amino-3-methyl-4h-imidazol-5-one;sulfuric acid Chemical compound OS(O)(=O)=O.CN1CC(=O)N=C1N MEVXSUZBFYZPHZ-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- NJXPYZHXZZCTNI-UHFFFAOYSA-N 3-aminobenzonitrile Chemical compound NC1=CC=CC(C#N)=C1 NJXPYZHXZZCTNI-UHFFFAOYSA-N 0.000 description 1
- AMKPQMFZCBTTAT-UHFFFAOYSA-N 3-ethylaniline Chemical compound CCC1=CC=CC(N)=C1 AMKPQMFZCBTTAT-UHFFFAOYSA-N 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- TWPMMLHBHPYSMT-UHFFFAOYSA-N 3-methyl-n-phenylaniline Chemical compound CC1=CC=CC(NC=2C=CC=CC=2)=C1 TWPMMLHBHPYSMT-UHFFFAOYSA-N 0.000 description 1
- OOADUVYZMNLUQS-UHFFFAOYSA-N 4-[chloromethyl(dimethyl)silyl]benzonitrile Chemical compound ClC[Si](C)(C)C1=CC=C(C#N)C=C1 OOADUVYZMNLUQS-UHFFFAOYSA-N 0.000 description 1
- WDFQBORIUYODSI-UHFFFAOYSA-N 4-bromoaniline Chemical compound NC1=CC=C(Br)C=C1 WDFQBORIUYODSI-UHFFFAOYSA-N 0.000 description 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- ODGIMMLDVSWADK-UHFFFAOYSA-N 4-trifluoromethylaniline Chemical compound NC1=CC=C(C(F)(F)F)C=C1 ODGIMMLDVSWADK-UHFFFAOYSA-N 0.000 description 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 0 C=C(*CC*1)C1=C Chemical compound C=C(*CC*1)C1=C 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- SSDBBPWOGQXTDC-UHFFFAOYSA-O C[SH+](C)(CNc1cccc(CO)c1)c1ccccc1 Chemical compound C[SH+](C)(CNc1cccc(CO)c1)c1ccccc1 SSDBBPWOGQXTDC-UHFFFAOYSA-O 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- PNKUSGQVOMIXLU-UHFFFAOYSA-N Formamidine Chemical compound NC=N PNKUSGQVOMIXLU-UHFFFAOYSA-N 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 101100448208 Human herpesvirus 6B (strain Z29) U69 gene Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- BWROMPNXPAWQEP-UHFFFAOYSA-N chloro(chloromethyl)silane Chemical compound ClC[SiH2]Cl BWROMPNXPAWQEP-UHFFFAOYSA-N 0.000 description 1
- IMDRVFHBUYOUBF-UHFFFAOYSA-N chloromethyl-(3,4-dimethylphenyl)silane Chemical compound ClC[SiH2]C1=CC(=C(C=C1)C)C IMDRVFHBUYOUBF-UHFFFAOYSA-N 0.000 description 1
- VMKYGOVAEHFVAE-UHFFFAOYSA-N chloromethyl-(3-methoxyphenyl)-dimethylsilane Chemical compound COC1=CC=CC([Si](C)(C)CCl)=C1 VMKYGOVAEHFVAE-UHFFFAOYSA-N 0.000 description 1
- MBVPERNHUDOZTD-UHFFFAOYSA-N chloromethyl-dimethyl-(3-phenylphenyl)silane Chemical compound ClC[Si](C)(C)C1=CC=CC(C=2C=CC=CC=2)=C1 MBVPERNHUDOZTD-UHFFFAOYSA-N 0.000 description 1
- OCERXZWFJLUJQO-UHFFFAOYSA-N chloromethyl-dimethyl-(4-methylphenyl)silane Chemical compound CC1=CC=C([Si](C)(C)CCl)C=C1 OCERXZWFJLUJQO-UHFFFAOYSA-N 0.000 description 1
- YROJGFUEFVWIMV-UHFFFAOYSA-N chloromethyl-dimethyl-naphthalen-2-ylsilane Chemical compound C1=CC=CC2=CC([Si](C)(CCl)C)=CC=C21 YROJGFUEFVWIMV-UHFFFAOYSA-N 0.000 description 1
- ROZARLKLCTZCSC-UHFFFAOYSA-N chloromethyl-methyl-phenyl-propylsilane Chemical compound CCC[Si](C)(CCl)C1=CC=CC=C1 ROZARLKLCTZCSC-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000012973 diazabicyclooctane Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229950010033 ebselen Drugs 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229910001447 ferric ion Inorganic materials 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000001299 hyperoxygenation Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000006540 mitochondrial respiration Effects 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 231100000243 mutagenic effect Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- AXDMKUZXIFIODW-UHFFFAOYSA-N n-(3-ethenylphenyl)-2,2,2-trifluoroacetamide Chemical compound FC(F)(F)C(=O)NC1=CC=CC(C=C)=C1 AXDMKUZXIFIODW-UHFFFAOYSA-N 0.000 description 1
- NTNIUAHRHHQBSJ-UHFFFAOYSA-N n-[[dimethyl(phenyl)silyl]methyl]-n-phenylacetamide Chemical compound C=1C=CC=CC=1N(C(=O)C)C[Si](C)(C)C1=CC=CC=C1 NTNIUAHRHHQBSJ-UHFFFAOYSA-N 0.000 description 1
- BRHNLNBFECGZQB-UHFFFAOYSA-N n-[dimethyl(phenyl)silyl]-3-(ethylaminomethyl)-n-methylaniline Chemical compound CCNCC1=CC=CC(N(C)[Si](C)(C)C=2C=CC=CC=2)=C1 BRHNLNBFECGZQB-UHFFFAOYSA-N 0.000 description 1
- HCBWSJMWCRVFDC-UHFFFAOYSA-N n-[dimethyl(phenyl)silyl]-3-methylfuran-2-carboxamide Chemical class C1=COC(C(=O)N[Si](C)(C)C=2C=CC=CC=2)=C1C HCBWSJMWCRVFDC-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001979 organolithium group Chemical group 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
- 229940067157 phenylhydrazine Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940072033 potash Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 150000003377 silicon compounds Chemical class 0.000 description 1
- OLRJXMHANKMLTD-UHFFFAOYSA-N silyl Chemical compound [SiH3] OLRJXMHANKMLTD-UHFFFAOYSA-N 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- 229940068778 tocotrienols Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/0805—Compounds with Si-C or Si-Si linkages comprising only Si, C or H atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
Definitions
- the present invention relates to silylmethyl-aniline derivatives, their methods of manufacture, the pharmaceutical compositions containing them and their use as medicaments.
- the generation of highly reactive oxygenated etabolites is an essential feature of many components of normal metabolism (generation of energy metabolism by the mitochondrial respiration chain, detoxification of xenobiotics by cytochromes, destruction of microorganisms by phagocytosis, and even ovulation and fertilization) .
- this local toxicity of free radicals and other toxic derivatives of oxygen constitutes a path common to numerous pathologies such as damage caused by radiotherapy, hyperoxygenation syndromes (for example neonatal bronchopulmonary dysplasia), inflammatory reactions (cf. GB Buckley, Surgery, 1 13, 479, 1993), autoimmune diseases, toxic damage during the post ischemic reperfusion phases (JY Arigou et al. Arch. Mal. Coeur, 86, 105- 109, 1993; N. Kaul et al. J. Pharmacol. Tox. Methods, 30, 55-67, 1993), reperfusion of organs including transplanted organs, carcinogenesis (cf. H. Sies, Ang. Chem. Int. .
- antioxidant derivatives or free radical scavengers can play a beneficial role in the prevention and / or treatment of the pathologies mentioned above.
- vitamin E or tocopherols, tocotrienols, vitamin C, b-carotene, flavonoids such as quercetin, probucol or even ebselen. H. Sies, "Oxidative stress", Académie Press, 1991; A. Ong, L. Packer, "Lipid-soluble antioxidants: biochemistry and clinical applications", Birkhauser, 1992; B. Halliwell, Drugs, 42, 569, 1991 ; M. Santrucek, J. Krepelka, Drugs of the future, 13, 974, 1988).
- Certain aromatic amines have also been characterized as antioxidants.
- aniline and certain of its derivatives have found utility in delaying the oxidative aging of rubbers or in protecting certain chemicals against polymerizations induced by oxidants and / or free radicals.
- many of these derivatives have not found therapeutic application because of their low antioxidant potential compared to their toxic side effects; diphenylphenylene diamine (DPPD) is thus able to protect the oxidation of rabbit LDL in vivo and thus to retard the progression of atheromatous plaques, but its use in human clinic is excluded because of its mutagenic properties. (CP Sparrow et al. J. Clin. Invest., 89, 1885-1891, 1992).
- the Applicant has now discovered new aromatic silylmethylamines which have interesting pharmacological and therapeutic properties since these derivatives behave like antioxidants capable of protecting biological systems such as tissues, membranes, cells, structural and / or functional proteins and lipids from attacks caused by free radicals and other toxic oxygen derivatives.
- the very good efficacy of the compounds of the invention as antioxidants ((in particular their capacity to protect human LDL against oxidative modifications induced by copper or endothelial cells and their capacity to trap hydroxyl radicals) associated with their easy and inexpensive access by chemical synthesis, their stability and their low toxicity, makes them valuable for the treatment of pathologies in which peroxidation plays an initiating and / or aggravating role.
- the subject of the present invention is the use as a medicine of aromatic silylmylamines which correspond to the general formula (I):
- R represents a hydrogen atom; an aromatic residue such as phenyl or naphthyl which can be variously substituted; an alkyl residue containing from 1 to 20 carbon atoms in a straight or branched chain which may contain one or more unsaturations; and / or functional groups such as alcohol, ether, thiol, thioether, halogen (fluorine, chlorine or bromine), ketone, ester, amino, amide, carbamate, carbonate, urea, nitrile, nitro, sulfone, sulfonamide.
- a and A ⁇ 2 identical or different, represent an aryl group chosen from the following aromatic residues:
- the broken bond represents a bond between the aromatic nucleus and the nitrogen atom of formula (I) when it is Ar ⁇ and a bond between the aromatic nucleus and the silicon atom when this is A ⁇ 2-
- R4, R5, R-5 and R7 may be in different positions (ortho, meta or para) on the aromatic ring to which they are attached, each representing a hydrogen atom, an aromatic residue (for example a phenyl which may be variously substituted), an alkyl radical containing 1 to 20 carbon atoms in a straight or branched chain [may contain one or more unsaturations and / or functional groups such as alcohol, ether, thiol, thioether, halogen (s), ketone, ester, amino, amide, carbonate, carbamate , urea, nitrile, nitro, sulfone, sulfonamide], a hydroxyl radical (OH), thiol (SH), alkoxy (ORg), acyloxy (OCORg), thioether (SR'g), trifluoromethyl (CF3), halogen (chlorine, fluorine, iodine or bromine), a triple bond variously substituted, a
- X and Y identical or different, each represent a CFb, an oxygen or sulfur atom or an NRI Q residue in which RI Q represents a hydrogen, an alkyl or aryl group.
- the compounds of formula (I) containing one or more asymmetric centers have isomeric forms.
- the racemates and pure enantiomers of these compounds are also part of this invention.
- the invention also includes the salts, solvates (for example hydrates) and bioprecursors of these compounds acceptable for therapeutic use.
- salts acceptable for the therapeutic use of the amines of formula (I) mention will be made of the salts formed by addition with organic or mineral acids, for example the hydrochlorides, hydrobromides, sulfates, sulfonates, fumarates, maleates, tartrates and succinates.
- organic or mineral acids for example the hydrochlorides, hydrobromides, sulfates, sulfonates, fumarates, maleates, tartrates and succinates.
- bioprecursors as used in the present invention applies to compounds of formula (I), but which, when administered to an animal or to a human being, are converted in the organism into a compound of formula
- the present invention describes a new class of antioxidants which differs from the prior art by their chemical structure since the derivatives forming part of the present invention are aromatic silyiamines which have never been described as being able to be useful for the treatment both curative as preventive of pathologies linked to oxidation or to the deleterious effects of free radicals.
- most of the compounds forming part of the present invention are represented by new molecules, the structure and the manufacturing process of which must also be considered as an integral part of the present invention.
- Ari represents a phenyl, an o-methyl-phenyl, an O-chlorophenyl, an o, p dichlorophenyl, an o-methoxy phenyl or an o (hydroxymethylphenyl) and simultaneously that R2 and R3 represent a methyl, and R ⁇ represents H, CH3, or C2H5, so Ar2 must be different from C 6 H 5 .
- the derivatives of general formula (I) are generally prepared by condensation of an aromatic amine of general formula (II):
- R3, R4 and Ar2 are described as above and Z represents a carrying group such as Cl, Br, I, OMs, OTs, OTf.
- Ari is defined as above with a halomethylsilane of formula (III) in the presence of a strong base such as for example n-butyllithium, sec-butyllithium, lithium diisopropylamide, sodium amide, in an anhydrous aprotic solvent such as tetrahydrofuran, ether, dimethoxyethane, optionally in the presence of DABCO, TMEDA or HMPT, at a temperature between - 78 ° and 20 ° C according to techniques and processes well known to those skilled in the art who, between other, indicate that it is often preferable to mix the strong base with the amine of formula (I) before introducing the halomethylethylsilane of formula (IIa); either indirectly, by initial condensation of a derivative of formula (Ilb):
- a strong base such as for example n-butyllithium, sec-butyllithium, lithium diisopropylamide, sodium amide
- a base such as for example sodium or potassium hydride in an anhydrous aprotic solvent such as tetrahydrofuran, or dimethylformamide at a temperature between - 20 ° C and 20 ° C followed by deprotection of the trifluoroacetamide thus formed by reaction with reagents well known for this type of transformation such as potassium hydroxide or sodium hydroxide in methanol at a temperature between 0 and 50 ° C or still the use of reducing agents such as for example lithium aluminum hydride in ether or tetrahydrofuran or sodium borohydride in an alcoholic solvent such as ethanol.
- a base such as for example sodium or potassium hydride in an anhydrous aprotic solvent such as tetrahydrofuran, or dimethylformamide
- reagents well known for this type of transformation such as potassium hydroxide or sodium hydroxide in methanol at a temperature between 0 and 50 ° C or still the use of reducing agents such as for example lithium aluminum
- a particularly preferred method for the preparation of derivatives of formula (I) in which R 1 represents an alkyl substituent which can be variously substituted consists in condensing an intermediate amide of general formula (Ile)
- R ′ represents a protective group such as formamidine (cf. AI Meyer, S. Hellering, Tetrahedron Lett., 22, 5119, 1981) with a strong base such as for example butyllithium secondary in tetrahydrofuran or ether in the presence of TMEDA and then to condense the organolithium thus formed with a halogenosilane of general formula (V):
- the derivatives of the present invention can also be prepared by reaction of an aromatic amine of general structure (VI):
- R2 is described as above and M represents Li, Na, K, MgCl, MgBr or Mgl according to a method previously described for the preparation of trimethysilylmethyl-aniline (Cfr. J. Eisch, CS Chiv, J. Organomet. Chem. 358 , C1-C5, 1988).
- Silylated intermediates of structure (III), (V) or (VII) are available or prepared by techniques and methods well known in the chemistry of organosilylates and are described in "Silicon reagents in organic synthesis” (EW Calvin, Académie Press, 1988), “The chemistry of organic silicon compounds” (S. Pata ⁇ , Z. Rappoport, J. Wiley, 1989) and “Silicon reagents for organic synthesis” (WP Weber, Springer Verlag, 1983).
- a compound according to the invention in the form of a salt, for example in the form of a salt formed by addition with an acid
- this can be achieved by treating the free base of general formula (I) with an appropriate acid, preferably in equivalent amount, or by creatinine sulfate in an appropriate solvent.
- the new compounds of general formula (I) When the new compounds of general formula (I) have one or more asymmetric centers, they can be prepared in the form of a racemic mixture or in the form of enantiomers, either by enantioselective synthesis or by resolution.
- the compounds of formula (I) having at least one asymmetric center can for example be separated into their enantiomers by the usual techniques such as the formation of diastereomeric pairs by formation of a salt with an optically active acid such as the acid (- ) di-p-toluoyl-1-tartaric, (+) di-p-toluoyl-tartaric acid, (+) camphor sulfonic acid, (-) camphor sulfonic acid, (+) phenylpropionic acid , (-) phenylpropionic acid, followed by fractional crystallization and regeneration of the free base.
- an optically active acid such as the acid (- ) di-p-toluoyl-1-
- the compounds of formula (I) can be purified by the usual methods, for example by crystallization (in particular when the compounds of formula (I) are isolated in the form of salt), chromatography or extraction.
- Acetic anhydride (26 g, 130 mmol) is added slowly to a solution of aniline (9.3 g; 100 mmol) and triethylamine (15, 15 g; 150 mmol) in 125 ml of anhydrous dichloromethane at 0 ° vs. After 3 hours at 20 ° C., the reaction medium is diluted with dichloromethane (300 ml) and washed with a 1N hydrochloric acid solution, then three times with 350 ml of a saturated aqueous solution of sodium chloride. The organic phase is dried over magnesium sulfate, filtered and evaporated. The solid obtained is purified by chromatography on a silica column to give 12.15 g of N-acetyl aniline.
- Step B Preparation of phenylI-dimethyl-silyP-methyll acetyl-phenylamine (ÎB
- a solution of N-acetyl aniline (12 g; 89 mmol) in 100 ml of anhydrous dimethyl formamide is added dropwise to a suspension of sodium hydride (106 mmol; 4.24 g of a 60% suspension in the oil which is washed beforehand with dry hexane) in 100 ml of DMF at 0 ° C.
- the reaction medium is stirred for 1 hour at 20 ° C then the chloromethyl phenyl dimethyl-silane (25 g; 135 mmol) is added to the reaction medium which is stirred at 90 ° C for 16 hours, then brought back to 20 ° C and diluted with 500 ml of ether and washed with water.
- the organic phase is dried over magnesium sulfate, filtered and evaporated.
- the derivative (3) was prepared according to the procedures described in Example 1 but using chloromethyl- [(4-methylthio-phenyl) dimethyl] -silane in step B.
- the derivative 4 is prepared according to the procedures described in Example 1 but using the cMoromémyl - [(4-dimémyla ⁇ nmo-phenyl) -diméthyl] -silane in step B.
- the derivative (5) is prepared according to the procedures described in Example 1 but using chloromethyl [(4-trifluoromethyl-phenyl) -dimethyl] -silane in step B.
- the derivative (6) is prepared according to the procedures described in Example 1 but using 4-trifluoromethyl-aniline in place of the aniline in the step
- the derivative (7) was prepared according to the procedures described in Example 1 but using 3-methoxy-aniline instead of aniline in step A.
- the derivative (9) was prepared according to the method described in Example 1 except that in step A, the acetic anhydride is replaced by formic anhydride and that in step B, the the electrophile used is choromethyl - [(2-ethylphenyl) -dimethyl] -silane.
- the derivative (10) is prepared according to the method described in Example 1 except that, in step A, 3-ethyl-aniline replaces aniline, formic anhydride replaces acetic anhydride and in step B, the electrophile used is chloromethyl [- (4-methyl-phenyl) -dimethyl] -silane.
- Compound J_l is prepared according to the method described in Example 1 except that acetic anhydride is replaced by formic anhydride and the aniline is replaced by 1-naphthamine in step A.
- Compound J12 is prepared by condensation of 8-quinoIinyl-formamide with chloromethyl- (phenyl-dimethyl) -silane followed by reduction of the amide according to the methods described as steps B and C in Example 1.
- the derivative J is prepared from 3-methyl-aniline, trifluoroacetic anhydride and chloromethyl- (phenyl-dimethyl) -silane according to the method described in Example 13.
- Compound 15 is prepared by condensation of 4-bromo-aniline with trifluoroacetic anhydride then with chloromethyl (phenyl-dimethyl) - silane followed by deprotection using lithium aluminum hydride according to the procedures described in Example 1.
- Compound 16 is prepared by condensation of 3-cyanoaniline successively with trifluoroacetic anhydride and chloromethyl (phenyl-dimethyl) -silane according to the procedures described in steps A and B of Example 1, followed by deprotection with level of the trifluoroanilide thus formed by sodium borohydride in absolute ethanol at 20 ° C for 4 hours.
- Derivative 18 was prepared by initial condensation of 3- (formyl) -N- (trifluoroacetyl) -aniline with chloromethyl- (dimethyl-phenyl) -silane (according to the procedure used in step B of Example 1 ) followed by the reaction of the intermediate thus formed with an excess of sodium borohydride in methanol.
- nitrile 16 15 g, 41.4 mmol
- DiBAl-H Aldrich, 1.0 M in toluene, 83 ml, 124.3 mmol , 3éq.
- the resulting solution is stirred for 3 hours at 19 room temperature.
- 30 ml of 5N hydrochloric acid are then added and the medium is vigorously stirred for approximately 2 hours.
- the aqueous phase is brought back to basic pH with concentrated sodium hydroxide and then extracted with ethyl acetate.
- the organic phase is then washed with water and then dried over magnesium sulfate, filtered and evaporated.
- the oil obtained (9.8 g; 88%) is sufficiently pure to be directly usable without further purification.
- Flash purification of the oil obtained on a silica column makes it possible to obtain, in the majority fraction, the expected product in the form of a light yellow oil (300 mg; 27%).
- Derivative 20 is prepared by condensation of N- (trifluoroacetyl) -2-naphthylamine with chloromethyl- (dimethyl-phenyl) -silane (according to the procedure described in step B of Example 1) followed by deprotection of the intermediary thus formed with alcoholic potash.
- IR (Film, cm-1) 3414; 3050; 2960; 2802; 1630; 1523; 1250; 833.
- Compound 2! is prepared by condensation of 4- (phenyl) -N- (trifluoroacetyl) -aniline with chloromethyl- (phenyl-dimethyl) -silane according to the procedure described in step B of Example 1, followed by deprotection of aniline by reaction with sodium borohydride at 20 ° C in ethanol.
- IR (Film, cm-1) 3414; 3050; 2960; 2802; 1630; 1523; 1250; 833.
- Derivative 22 is prepared according to the same procedure as derivative 21 but using chloromethyl- (4-bromo ⁇ henyl) -dimethyl-silane as starting material.
- EXAMPLE 23 is prepared according to the same procedure as derivative 21 but using chloromethyl- (4-bromo ⁇ henyl) -dimethyl-silane as starting material.
- Derivative 23 is prepared by alkylation of 3-vinyl-N- (trifluoroacetyl) -aniline with chloromethyl-phenyl-dimethyl-silane according to the procedure described in step B of Example 1, followed by deprotection of the aniline by reaction with lithium aluminum hydride in ether.
- Derivative 24 is obtained by condensation of 3- (oxazol-4-yl) -N- (trifluoroacetyl) -aniline with chloromethyl-phenyl-dimethyl-silane according to the procedure described in step B of Example 1 followed deprotection of aniline by reaction with sodium borohydride in ethanol at 20 ° C.
- Compound 25 is prepared by condensation of N- (trifluoroacetyl) -6-aminoquinoline with chloromethyl-dimethyl-phenyl-silane according to the procedure described in step B of Example 1, followed by deprotection of the amine by reaction with sodium borohydride in ethanol at 20 ° C.
- Compound 26 is prepared by condensation of the amino N- (trifluoroacety) -6-benzothiazolyl with chloromethyl-dimethyl-phenyl-silane according to the procedure described in step B of Example 1, followed by deprotection of the amine by reaction with sodium borohydride in ethanol at 20 ° C.
- n-butyllithium (62.5 ml of a 1.6 M solution in hexane, ie 100 mmol) is added dropwise to a solution of 4 methoxyaniline (11.07 g; 90 mmol) in 100 ml of anhydrous tetrahydrofuran at 0 ° C under an argon atmosphere.
- the reaction medium is stirred for 1 hour at 20 ° C. then 25 g of coromethyl-dimethyl-phenyl-silane dissolved in 100 ml of tetrahydrofuran are introduced into the reaction medium which is stirred for 20 hours at 60 ° C.
- reaction medium is brought to 20 ° C., diluted in ethyl ether (300 ml) and washed with water, then three times with a saturated aqueous NaCl solution.
- the organic phase is dried over magnesium sulfate, filtered and concentrated under reduced pressure.
- the residue is distilled (145-150 ° C / 0.5 mm Hg) to give the product 27 (22 g; 90%).
- Derivative 29 is prepared from N- (3-methyl-phenyl) -aniline and chloromethyl- (dimethyl-phenyl) -silane according to the procedure described in Example 27.
- Compound 30 is prepared from 4-methyl-aniline and chloromethyl- (dimethyl-phenyl) -silane according to the procedure described in Example 27.
- Compound 3_1 is prepared from 2-methyl aniline and chloromethyl-dimethyl- (4-methyl-phenyl) -silane according to the experimental procedure described in Example 27.
- Compound 32 is prepared by condensation of 3-methyl-aniline with cluoromemyl- (2,6-dimethyl-phenyl) -dimethyl-silane according to the experimental procedure described in Example 27.
- Derivative 34 is prepared from 3-methyl aniline and chloromethyl- (3-methoxy-phenyl) -dimethyl-silane according to the experimental procedure described in Example 27.
- Derivative 35 is prepared by condensation of aniline with chloromethyl- (3-naphthyl) -dimethyl-silane according to the experimental procedure described in Example 27.
- Compound 36 is prepared by condensation of 4-tertiobutyl-aniline with chloromethyl-dimethyl-phenyl-silane according to the experimental procedure described in Example 27.
- Compound 38 is prepared by condensation of 3-methyl-aniline with chloromethyl-methyl-propyl-phenyl-silane according to the experimental procedure described in Example 27.
- the antioxidant activity of the derivatives of the present invention has been more particularly demonstrated on microsomes of rat livers, following a chemical peroxidation induced by ferric ions and on human LDL.
- the inhibitory action of the compounds of the present invention with respect to the oxidation of human LDL has been demonstrated whether it is following a chemical oxidation by copper sulphate or following a biological oxidation by human endothelial cells from umbilical veins.
- Endothelial cells, line ECV304 (ATCC CRL-1998) are cultured in wells 35 mm in diameter in DMEM-HEPES-Glutamax I medium supplemented with 10% fetal calf serum, penicillin-streptomycin 100 IU / ml - 100 ⁇ g / ml, and fungizone 2.5 ⁇ g / ml to a sub-confluent state.
- the cells are then incubated for 24 hours in DMEM-HEPES-Glutamax I medium containing ultroser G 2%; then, the oxidation of LDL is triggered by their contact with the cells for 24 hours in the HAM F-10 nutritive medium (Breugnot C, Maziere C, Salmon S., Auclair M., Santus R., Morliere P., Lenaers A. and Mazière JC: Phenothiazines inhibits copper and endothelial cell-induced peroxidation of low density lipoprotein. A comparative study with probucol, butylated hydroxytoluene and vitamin E. Biochemical Pharmacology, 1990, 40: 1975-1980).
- the samples are heated for 30 minutes at 95 ° C., the TBARs are extracted with butanol-1 and quantified by fluorimetry (excitation wavelengths 515 nm, emission 548 nm, Perkin Elmer LS-50B spectrofluorimeter). The results are expressed in nmol malondialdehyde equivalent / mg LDL proteins.
- the antioxidant activity of the compounds of the present invention in this model was studied in comparison with vitamin E. As the few illustrative examples shown in the table below show, the compounds of the present invention have been shown to be superior to the vitamin E in this test.
- lipids such as human microsomes or LDL against oxidative modifications and in particular during biological oxidation mediated by human endothelial cells.
- the antioxidant properties, in particular at the LDL level, of the derivatives of the present invention allow their use as medicaments in the treatment and / or prevention of atherosclerosis including its various peripheral vascular localizations, coronary or cerebral, diseases due vascular complications linked to lipoproteins, but also pathologies in which a membrane lipid peroxidation plays an initiating and / or aggravating role such as ischemic heart disease, organ reperfusion, including transplant, traumatic ischemic pathologies of the central nervous system or peripheral, autoimmune diseases and metabolic diseases such as diabetes, and in general all dyslipidemias.
- the derivatives of the present invention have been shown to be particularly effective in neutralizing hydroxyl radicals (OH): this is how, in a test making it possible to determine the ability of compounds to trap the hydroxyl radical (method using the assay of the radical 2-hydroxy-5,5 dimethyl-1-pyrroline-N-oxide by RPE according to Miyagawa et al., J. Clin.
- Example 13 38 Hydroxyl radicals constitute a source of extremely aggressive radicals at the cellular and molecular levels, and therefore the compounds of the present invention which have the advantage of being both inhibitors of lipid peroxidation and free radical trappers are also found. their usefulness for the treatment and / or prevention of acute or chronic inflammatory diseases, as well as in dermatology and dermo-cosmetology and in the treatment of various pathologies such as certain forms of cancer (in particular tumors linked to ionizing radiation such as than certain skin cancers), tissue aging (especially skin aging), and certain forms of degeneration such as Parkinson's or Alzheimer's disease.
- various antioxidants such as vitamin E have shown a protective effect in a model of MPTP-induced neurotoxicity (cf. TL Pe ⁇ y et al, Neurosc. Letters, 60, 109, 1985) model considered to be predictive of neuro diseases - degenerative (cf. Neuroscience Facts, 3 (23), 89, 1992).
- the present invention also relates to pharmaceutical compositions containing as active ingredient a compound of general formula I or one of its acceptable salts for pharmaceutical use, mixed or associated with a suitable excipient.
- These compositions can take, for example, the form of solid, liquid compositions, emulsions, lotions or creams.
- compositions for oral administration tablets, pills, powders (gelatin capsules, cachets) or granules can be used.
- the active principle according to the invention is mixed with one or more inert diluents, such as starch, cellulose, sucrose, lactose or silica, under a stream of argon.
- inert diluents such as starch, cellulose, sucrose, lactose or silica
- These compositions can also comprise substances other than diluents, for example one or more lubricants such as magnesium stearate or talc, a dye, a coating (dragees) or a varnish.
- compositions for oral administration there may be used pharmaceutically acceptable solutions, suspensions, emulsions, syrups and elixirs containing inert diluents such as water, ethanol, glycerol, vegetable oils or oil paraffin.
- inert diluents such as water, ethanol, glycerol, vegetable oils or oil paraffin.
- These compositions can include substances other than diluents, for example wetting, sweetening, thickening, flavoring or stabilizing products.
- the sterile compositions for parenteral administration can preferably be aqueous or non-aqueous solutions, suspensions or emulsions.
- solvent or vehicle water, propylene glycol, polyethylene glycol, vegetable oils, in particular olive oil, injectable organic esters, for example ethyl oleate or other suitable organic solvents.
- These compositions can also contain adjuvants, in particular wetting agents, isotonizers, emulsifiers, dispersants and stabilizers.
- Sterilization can be done in several ways, for example by aseptic filtration, by incorporating sterilizing agents into the composition, by irradiation or by heating. They can also be prepared in the form of sterile solid compositions which can be dissolved at the time of use in sterile water or any other sterile injectable medium.
- compositions for rectal administration are suppositories or rectal capsules which contain, in addition to the active product, excipients such as cocoa butter, semi-synthetic glycerides or polyethylene glycols.
- compositions for topical administration can be, for example, creams, lotions, eye drops, mouthwashes, nasal drops or aerosols.
- the doses depend on the desired effect, on the duration of the treatment and on the route of administration used; they are generally between 0.001 g and 1 g (preferably between 0.005 g and 0.25 g) per day, preferably orally for an adult with unit doses ranging from 0.1 mg to 500 mg of active substance, preferably from 1 mg to 50 mg. In general, the doctor will determine the appropriate dosage based on age, weight and all other factors specific to the subject to be treated.
- the following examples illustrate compositions according to the invention [in these examples, the term "active component designates one or more (generally one) of the compounds of formula (I) according to the present invention]:
- They can be prepared by direct compression or by passing through wet granulation.
- the direct compression procedure is preferred, but it may not be suitable in all cases depending on the doses and the physical properties of the active component.
- the active component is passed through a sieve with a mesh opening of 250 ⁇ m on a side, it is mixed with the excipients and it is compressed using 6.0 mm punches. Tablets with other mechanical strengths can be prepared by varying the compression weight with the use of appropriate punches.
- the active component is passed through a sieve with a mesh opening of 250 ⁇ m and mixed with lactose, starch and pregelatinized starch.
- the mixed powders are moistened with purified water, they are granulated, dried, sieved and mixed with magnesium stearate.
- the lubricated granules are put into tablets as for the formulas by
- a coating film can be applied to the tablets using suitable film-forming materials, for example methylcellulose or hydroxypropyl methylcellulose, according to conventional techniques. Sugar tablets can also be coated.
- the active component is passed through a sieve with a mesh opening of 250 ⁇ m and mixed with the other substances.
- the mixture is introduced into hard gelatin capsules No. 2 on an appropriate filling machine.
- Other dosage units can be prepared by changing the filling weight and, if necessary, changing the size of the capsule.
- the active component, the buffer, the flavor, the color and the preservative are dissolved in part of the water and the glycerin is added. The remainder of the water is heated to 80 ° C. and the sucrose is dissolved therein and then cooled. The two solutions are combined, the volume is adjusted and mixed. The syrup obtained is clarified by filtration.
- Witepsol H15 supplement to 1.0 g * Brand marketed for Adeps Solidus of the European Pharmacopoeia.
- a suspension of the active component in Witepsol H 15 is prepared and introduced into a suitable machine with 1 g suppository molds.
- Sodium chloride can be added to adjust the tone of the solution and adjust the pH to maximum stability and / or to facilitate the dissolution of the active component by means of a dilute acid or alkali or by adding buffer salts. appropriate.
- the solution is prepared, clarified and introduced into suitable size vials which are sealed by melting the glass.
- the liquid for injection can also be sterilized by heating in an autoclave according to one of the acceptable cycles.
- the solution can also be sterilized by filtration and introduced into a sterile ampoule under aseptic conditions.
- the solution can be introduced into the ampoules in a gaseous atmosphere.
- the active component is micronized in a fluid energy mill and made into fine particles before mixing with lactose for tablets in a high energy mixer.
- the powder mixture is introduced into hard gelatin capsules No. 3 on an appropriate encapsulating machine.
- the contents of the cartridges are administered using a powder inhaler.
- Pressure aerosol with metering valve mg / dose for 1 can of micronized active ingredient 0.500 120 mg oleic acid Codex 0.050 12 mg trichlorofluoromethane for pharmaceutical use 22.25 5.34 g
- dichlorodifluoromethane for pharmaceutical use 60.90 14.62 g
- the active component is micronized in a fluid energy mill and placed in the form of fine particles.
- the oleic acid is mixed with the trichlorofluoromethane at a temperature of 10-1 ° C. and the micronized drug is introduced into the solution using a mixer with a high shearing effect.
- the suspension is introduced in measured quantity into aluminum aerosol cans on which are fixed appropriate metering valves delivering a dose of 85 mg of the suspension; dichlorodifluoromethane is introduced into the boxes by injection through the valves.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU29309/95A AU2930995A (en) | 1994-07-08 | 1995-07-07 | Silylmethyl-aniline derivatives, methods of preparation and use thereof as drugs |
EP95925028A EP0770084A1 (en) | 1994-07-08 | 1995-07-07 | Silylmethyl-aniline derivatives, methods of preparation and use thereof as drugs |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR94/08468 | 1994-07-08 | ||
FR9408468A FR2722198B1 (en) | 1994-07-08 | 1994-07-08 | 1 SILIVES OF SILYLMETHYL-ANILINES, MANUFACTURE, AND THEIR USE CO |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996001830A1 true WO1996001830A1 (en) | 1996-01-25 |
Family
ID=9465173
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1995/000916 WO1996001830A1 (en) | 1994-07-08 | 1995-07-07 | Silylmethyl-aniline derivatives, methods of preparation and use thereof as drugs |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0770084A1 (en) |
AU (1) | AU2930995A (en) |
CA (1) | CA2194677A1 (en) |
FR (1) | FR2722198B1 (en) |
WO (1) | WO1996001830A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005102358A3 (en) * | 2004-04-20 | 2007-03-01 | Rnd Pharmaceuticals | Silicone-substituted cox-2 selective inhibitors |
US7576215B2 (en) | 2003-12-12 | 2009-08-18 | Wyeth | Quinolines and pharmaceutical compositions thereof |
JP2011140475A (en) * | 2010-01-08 | 2011-07-21 | Fujifilm Corp | Charge transport material and organic electroluminescent element |
US20160280656A1 (en) * | 2007-01-10 | 2016-09-29 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4670421A (en) * | 1982-07-12 | 1987-06-02 | American Cyanamid Company | Antiatherosclerotic silanes |
EP0404134A1 (en) * | 1989-06-21 | 1990-12-27 | Dow Corning Toray Silicone Company, Limited | Organosilicon compounds and method for their preparation |
EP0464852A1 (en) * | 1990-07-05 | 1992-01-08 | Merrell Pharmaceuticals Inc. | Novel 2,6-di-alkyl-4-silyl-phenols as antiatherosclerotic agents and as antioxidants |
-
1994
- 1994-07-08 FR FR9408468A patent/FR2722198B1/en not_active Expired - Fee Related
-
1995
- 1995-07-07 AU AU29309/95A patent/AU2930995A/en not_active Abandoned
- 1995-07-07 EP EP95925028A patent/EP0770084A1/en not_active Withdrawn
- 1995-07-07 WO PCT/FR1995/000916 patent/WO1996001830A1/en not_active Application Discontinuation
- 1995-07-07 CA CA002194677A patent/CA2194677A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4670421A (en) * | 1982-07-12 | 1987-06-02 | American Cyanamid Company | Antiatherosclerotic silanes |
EP0404134A1 (en) * | 1989-06-21 | 1990-12-27 | Dow Corning Toray Silicone Company, Limited | Organosilicon compounds and method for their preparation |
EP0464852A1 (en) * | 1990-07-05 | 1992-01-08 | Merrell Pharmaceuticals Inc. | Novel 2,6-di-alkyl-4-silyl-phenols as antiatherosclerotic agents and as antioxidants |
Non-Patent Citations (3)
Title |
---|
CHEMICAL ABSTRACTS, vol. 115, no. 5, 5 August 1991, Columbus, Ohio, US; abstract no. 49790q, LIAO, R. ET AL.: "STUDY ON ORGANO-SILICON COMPOUNDS WITH BIOLOGICAL ACTIVITY. (X). SYNTHESIS OF N-HYDROCARBYL-N-DIMETHYLPHENYL-DIMETHYLSILYLMETHYLENE-2-FURAMIDE AND ITS BIOLOGICAL ACTIVITY" page 861; * |
GAODENG XUEXIAO HUAXUE XUEBAO, vol. 11, no. 10, 1990, pages 1072 - 1075 * |
SATO, Y. ET AL.: "REACTION OF N-(TRIORGANOSILYLMETHYL)DIALKYLAMINES WITH BENZYNE", THE JOURNAL OF ORGANIC CHEMISTRY, vol. 41, no. 22, 1976, pages 3559 - 3564 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7576215B2 (en) | 2003-12-12 | 2009-08-18 | Wyeth | Quinolines and pharmaceutical compositions thereof |
WO2005102358A3 (en) * | 2004-04-20 | 2007-03-01 | Rnd Pharmaceuticals | Silicone-substituted cox-2 selective inhibitors |
US7964738B2 (en) | 2004-04-20 | 2011-06-21 | Silamed, Inc. | Pharmaceutical compositions and methods of use of lipophilic, silicon-substituted, cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs and derivatives |
US20160280656A1 (en) * | 2007-01-10 | 2016-09-29 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
US9890123B2 (en) * | 2007-01-10 | 2018-02-13 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
JP2011140475A (en) * | 2010-01-08 | 2011-07-21 | Fujifilm Corp | Charge transport material and organic electroluminescent element |
Also Published As
Publication number | Publication date |
---|---|
CA2194677A1 (en) | 1996-01-25 |
FR2722198B1 (en) | 1996-10-04 |
AU2930995A (en) | 1996-02-09 |
FR2722198A1 (en) | 1996-01-12 |
EP0770084A1 (en) | 1997-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR2669336A1 (en) | NOVEL OXAZOLO PYRIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | |
CA2100944A1 (en) | 3-(hydroxybenzylidenyl)-indoline-2-ones, their preparation and the pharmaceutical compositions containing them | |
CA1197247A (en) | Preparation process of new imidazotetrazinone derivatives thus obtained | |
EP0289380A1 (en) | Aryl-heteroaryl-carbinol derivatives having an analgesic activity | |
CH683996A5 (en) | aminophosphonates substituted derivatives, process for their preparation and pharmaceutical compositions containing them. | |
FR2673625A1 (en) | NOVEL ACYLAMINOPHENOL DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
EP1007524B1 (en) | Indole derivatives as 5-ht1b and 5-ht1d agonists | |
WO1996001830A1 (en) | Silylmethyl-aniline derivatives, methods of preparation and use thereof as drugs | |
CA2074365A1 (en) | Urea derivatives, their preparation and drugs containing them | |
WO1995001334A1 (en) | Arylamine-derived indole compounds as selective 5ht1d and 5ht1b receptor ligands | |
EP0582515A1 (en) | Monohydrate of the disodium salt of 4-chlorophenylthiomethylene-bisphosphonic acid, its preparation and pharmaceutical compositions containing it | |
EP0143016B1 (en) | Derivatives of 4-(3-alkynyloxy-2-hydroxy-propyl)-piperazin-1-yl-n-phenyl acetamide, their preparation and their therapeutical use | |
EP0138684B1 (en) | 2-(n-pyrrolidino)-3-isobutoxy-n-phenyl-substituted n-benzylpropyl amines, their preparation and their pharmaceutical use | |
CA2167821A1 (en) | New silylated benzylamine derivatives and their salts; process for producing the same and pharmaceutical compositions containing them | |
WO1996016957A1 (en) | 3,4-dihydro-2,5,7,8-tetramethyl-benzopyran-6-ol derivatives for use as drugs | |
BE1003518A3 (en) | NOVEL DERIVATIVES OF METHOXYCARBONYL-2-N, N'-DI- (TRIMETHOXYBENZOYLE) PIPERAZINE, A PROCESS FOR THEIR PREPARATION AND THERAPEUTIC COMPOSITIONS CONTAINING SAME. | |
LU87604A1 (en) | NOVEL CARBONYL-2 N, N'-DI- (TRIMETHOXYBENZOYLE) PIPERAZINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THERAPEUTIC COMPOSITIONS CONTAINING THE SAME | |
EP2084125A1 (en) | Aminobenzocycloheptene derivatives, methods for preparing the same and uses thereof in therapy | |
FR2781228A1 (en) | New unsaturated phosphonates derived from tryptophan, useful as selective Ras prenylation inhibitors, e.g. for treating cancer or arteriosclerosis | |
FR2745572A1 (en) | New benzylamine sulphonamide derivatives | |
EP0347305B1 (en) | [(Aryl-4-piperazinyl-1)-2-ethoxy]-3 p cymene, the ortho-, meta-, para-monosubstituted or disubstituted phenyl ring derivatives, process for their preparation and medicaments containing the same as the active principle | |
FR2571965A1 (en) | DRUGS BASED ON NOVEL 4 H-DIOXINO- (4,5-C) -PYRIDINE DERIVATIVES. | |
WO1999006376A1 (en) | Novel sulphonamide derived from substituted anilines useful as medicines | |
CH624389A5 (en) | Process for the preparation of new methylamine derivatives | |
FR2719047A1 (en) | New benzylamine derivatives, their manufacturing process and the pharmaceutical compositions containing them. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1997 765544 Date of ref document: 19970108 Kind code of ref document: A Format of ref document f/p: F Ref country code: CA Ref document number: 2194677 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2194677 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995925028 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995925028 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995925028 Country of ref document: EP |